Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...

CAMBRIDGE, England, February 19, 2026--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to ...

The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...

Synthego, a provider of genome editing solutions, and bit.bio, a synthetic biology firm, said that they are expanding their strategic partnership to work on a platform for implementing synthetic ...

Automata, a leading robotics and automation company powering life sciences labs, today announced it is partnering with bit.bio, to automate a key aspect of the manufacturing process of their iPSC ...

Bit Bio, the new startup that pitches itself as the “enter button for the keyboard to the software of life,” only needed three weeks to raise its latest $41.5 million round of funding. Originally ...

Today bit.bio welcomed three new members to its Board of Directors, who bring their respective experience of turning world class science into new industries and company growth. The new directors will ...

CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...